Vera Therapeutics (NASDAQ:VERA) Insider Robert Brenner Sells 2,151 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) insider Robert Brenner sold 2,151 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $90,298.98. Following the completion of the transaction, the insider directly owned 50,947 shares of the company’s stock, valued at approximately $2,138,755.06. This trade represents a 4.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Vera Therapeutics Stock Performance

Vera Therapeutics stock traded down $0.69 on Wednesday, hitting $41.68. The company’s stock had a trading volume of 776,869 shares, compared to its average volume of 897,432. Vera Therapeutics, Inc. has a one year low of $18.53 and a one year high of $56.05. The firm has a market cap of $2.92 billion, a P/E ratio of -10.45 and a beta of 1.16. The company has a quick ratio of 12.21, a current ratio of 12.21 and a debt-to-equity ratio of 0.19. The company has a fifty day moving average price of $46.63 and a 200-day moving average price of $35.30.

Hedge Funds Weigh In On Vera Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC grew its holdings in shares of Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in Vera Therapeutics during the 4th quarter worth about $46,000. Aster Capital Management DIFC Ltd bought a new stake in Vera Therapeutics during the 4th quarter worth about $71,000. Quantbot Technologies LP acquired a new stake in Vera Therapeutics in the 2nd quarter valued at about $51,000. Finally, Sandia Investment Management LP acquired a new stake in Vera Therapeutics in the 4th quarter valued at about $127,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on VERA. Evercore raised their price target on shares of Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Pivotal Research set a $73.00 price target on Vera Therapeutics in a research note on Friday, December 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Wednesday, January 21st. The Goldman Sachs Group boosted their target price on shares of Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Finally, Wedbush upped their target price on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $77.18.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.